← FDA DRUG APPROVALS

FDA ANDA · ANDA220232

EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATE

Sponsor: LAURUS

APPLICATION
ANDA220232
TYPE
ANDA
ORIGINAL APPROVAL
2026-03-04
LATEST ACTION
2026-03-04
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATEPrescription
EMTRICITABINE 200MG, RILPIVIRINE HYDROCHLORIDE EQ 25MG BASE, TENOFOVIR DISOPROXIL FUMARATE 300MG · TABLET · ORAL

Approval history

2026-03-04UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →